AI-powered digital pathology for faster, more accurate diagnostics.

Deciphex is transforming pathology through AI-driven digital workflows and a global network of elite pathologists. Their platforms, Diagnexia and Patholytix, deliver rapid remote diagnostics and streamline drug development for leading healthcare and pharmaceutical organizations. By automating routine tasks and enhancing diagnostic precision, Deciphex helps address the global shortage of pathologists and improves patient care across the world.

Why we’re excited about them

With top pharma clients, strong clinical growth and expanding international labs, Deciphex is scaling rapidly. Their AI platform and 200-strong pathologist network unlock efficiency in a supplyconstrained market.

Molten Ventures Growth Fund First Close

Molten Ventures announces the first close of our Growth Fund at £175 million, including a £75 million cornerstone commitment from the British Business Bank. 

“There is no shortage of exceptional founders or technology businesses in the UK and Europe; what they too often lack is sufficient growth capital to help them become global leaders. This Fund gives Molten greater firepower to back our highest-conviction companies at Series B and beyond, build meaningful ownership positions and channel capital into the next generation of growth.” - 
Ben Wilkinson, CEO of Molten
Read the press release here